Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP)’s traded shares stood at 3.53 million during the latest session, with the company’s beta value hitting 2.13. At the last check today, the stock’s price was $0.16, to imply an increase of 3.53% or $0.01 in intraday trading. The TNXP share’s 52-week high remains $29.76, putting it -18500.0% down since that peak but still an impressive 18.75% since price per share fell to its 52-week low of $0.13. The company has a valuation of $3.42M, with an average of 42.38 million shares in intraday trading volume over the past 10 days and average of 19.74 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Tonix Pharmaceuticals Holding Corp (TNXP), translating to a mean rating of 1.00. Of 5 analyst(s) looking at the stock, 0 analyst(s) give TNXP a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 4 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -2.93.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) trade information
After registering a 3.53% upside in the latest session, Tonix Pharmaceuticals Holding Corp (TNXP) has traded red over the past five days. The 5-day price performance for the stock is -2.14%, and -68.38% over 30 days. With these gigs, the year-to-date price performance is -98.79%. Short interest in Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) saw shorts transact 1.3 million shares and set a 0.55 days time to cover.
Tonix Pharmaceuticals Holding Corp (TNXP) estimates and forecasts
Looking at statistics comparing Tonix Pharmaceuticals Holding Corp share performance against respective industry, we note that the company has outperformed competitors. Tonix Pharmaceuticals Holding Corp (TNXP) shares are -98.54% down over the last 6 months, with its year-to-date growth rate higher than industry average at 99.13% against 20.00%. Revenue is forecast to grow 95.00% this quarter before jumping 89.20% for the next one. The rating firms project that company’s revenue will grow 59.40% compared to the previous financial year.
Revenue forecast for the current quarter as set by 3 analysts is 3.08M. Meanwhile, for the current quarter, a total of 3 analyst(s) estimate revenue growth to 3.4M.Earnings reports from the last fiscal year show that sales brought in 3.99M and 3.78M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -22.80% before dropping -10.00% in the following quarter.
TNXP Dividends
Tonix Pharmaceuticals Holding Corp has its next earnings report out on 2024-Nov-07. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP)’s Major holders
Tonix Pharmaceuticals Holding Corp insiders hold 1.34% of total outstanding shares, with institutional holders owning 1.82% of the shares at 1.85% float percentage. In total, 1.82% institutions holds shares in the company.
